证券代码：600161 证券简称：天坛生物 公告编号：2025-004 朱弘一先生，现任中金公司投资银行部副总经理、保荐代表人。朱弘一先生曾参与 天坛生物非公开发行、东方财富可转债、中国船舶重大资产重组、中国海防重大资产重 组、八一钢铁重大资产重组、长城电子重组上市、韵达股份重组上市等项目。朱弘一先 生在保荐业务执业过程中严格遵守《证券发行上市保荐业务管理办法》等相关规定，执 业记录良好。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）于近日收到保荐机构中国国 际金融股份有限公司（以下简称"中金公司"）出具的《关于更换北京天坛生物制品股 份有限公司持续督导保荐代表人的说明》。 中金公司系公司 2021 年非公开发行股票项目的保荐机构，前次委派持续督导的保 荐代表人为陈超先生、夏雨扬女士。现夏雨扬女士因工作变动，不再继续担任公司持续 督导的保荐代表人，为保证持续督导工作的有序进行，中金公司委派朱弘一先生（简历 见附件）接替夏雨扬女士担任公司的持续督导保荐代表人，履行持续督导职责。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4]. Core Insights - The company reported a strong Q4 performance, with revenue and net profit exceeding expectations. For 2024, the company anticipates revenue of 60.34 billion yuan (up 16.47% year-on-year) and a net profit of 15.47 billion yuan (up 39.42 year-on-year) [7]. - The acquisition of Zhongyuan Ruide has enhanced the company's overall strength, adding a blood product manufacturing enterprise and increasing plasma collection capabilities [7]. - The company is actively expanding its plasma collection stations, achieving a total of 85 operational single plasma collection stations in 2024, with a plasma collection volume of 2,781 tons, representing a 15.15% year-on-year increase [7]. - The product line is being enriched, with new products expected to improve profit margins per ton of plasma collected [7]. - The profit forecasts for 2024-2026 have been revised upwards, with expected net profits of 15.47 billion yuan, 17.31 billion yuan, and 19.47 billion yuan respectively, reflecting the company's strong resource endowment and new product contributions [7]. Financial Data and Profit Forecast - Total revenue for 2023 is projected at 51.80 billion yuan, with a year-on-year growth rate of 21.6%. The net profit attributable to the parent company is expected to be 11.10 billion yuan, with a growth rate of 26.0% [3][9]. - For 2024, the company expects total revenue of 60.34 billion yuan and a net profit of 15.47 billion yuan, with corresponding EPS of 0.78 yuan [3][9]. - The gross profit margin is expected to remain stable at around 55% from 2024 onwards [3].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company reported a strong performance in Q4 2024, with revenue of 1.96 billion yuan, representing a year-on-year increase of 69.05%, and a net profit of 496 million yuan, up 129.77% year-on-year [2] - For the full year 2024, the company achieved revenue of 6.034 billion yuan, a year-on-year growth of 16.47%, and a net profit of 1.547 billion yuan, reflecting a year-on-year increase of 39.42% [1][2] - The growth in performance is attributed to increased product sales and price hikes [2] - The company has enhanced its plasma collection efforts, achieving a collection volume of 2,781 tons in 2024, a 15.15% increase year-on-year, which supports future growth [2] - The company has a robust pipeline of over ten products in development, including blood products and recombinant products, which are expected to strengthen its market position [3] Financial Summary - The company forecasts net profits of 1.688 billion yuan and 1.932 billion yuan for 2025 and 2026, respectively, with year-on-year growth rates of 9.17% and 14.43% [3] - The estimated earnings per share (EPS) for 2025 and 2026 are projected to be 0.85 yuan and 0.98 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 23 and 20 [3] - The revenue for 2025 is expected to reach 6.926 billion yuan, reflecting a growth rate of 14.79% [4]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company is expected to achieve a revenue of 6.034 billion RMB in 2024, representing a year-on-year growth of 16% [1] - The projected net profit attributable to shareholders is 1.547 billion RMB for 2024, reflecting a 39% increase compared to the previous year [1] - The company has successfully increased its plasma collection volume by 15.15% year-on-year, reaching 2,781 tons in 2024 [2] - The acquisition of Wuhan Zhongyuan Ruide has enhanced the company's competitive position in the industry [2] - Continuous investment in R&D has led to significant clinical progress, including the approval of a new product [3] Summary by Sections Performance Review - In 2024, the company anticipates a revenue of 6.034 billion RMB, a 16% increase from 2023, and a net profit of 1.547 billion RMB, up 39% [1] - The fourth quarter of 2024 is expected to see a revenue of 1.961 billion RMB, a 69% increase year-on-year, and a net profit of 495 million RMB, reflecting a 123% growth [1] Operational Analysis - The company has enhanced its plasma collection capabilities, achieving a total of 2,781 tons in 2024, supported by strategic partnerships with government and health authorities [2] - The acquisition of Wuhan Zhongyuan Ruide has added 13 product licenses to the company's portfolio, further strengthening its market position [2] R&D Investment - The company maintains a high level of R&D investment, with recent advancements including the approval of a new coagulation product and the completion of a Phase III clinical trial for another product [3] Profit Forecast and Valuation - The profit forecast for 2024-2026 has been revised upwards, with expected net profits of 1.547 billion RMB in 2024, 1.742 billion RMB in 2025, and 1.958 billion RMB in 2026 [4] - The projected EPS for 2024-2026 is 0.78, 0.88, and 0.99 RMB, with corresponding PE ratios of 25, 22, and 20 [4]

Financial Performance - Total operating revenue for 2024 reached CNY 603,352.86 million, an increase of 16.47% compared to the previous year[3] - Net profit attributable to shareholders increased by 39.42% year-on-year, amounting to CNY 154,743.19 million[3] - Basic earnings per share rose to CNY 0.78, reflecting a 39.42% increase from CNY 0.56 in the previous year[3] - The weighted average return on equity increased by 2.87 percentage points to 14.80%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,584,794.47 million, up 11.70% from the beginning of the period[3] - The company's equity attributable to shareholders increased to CNY 1,113,697.14 million, a growth of 13.38%[3] - The net asset value per share decreased by 5.52% to CNY 5.63, adjusted for capital reserve conversion[3][4] Plasma Collection - The company collected 2,781 tons of plasma in 2024, a year-on-year increase of 15.15%[5] - The company operates 85 plasma collection centers, including subsidiaries, to enhance plasma collection capacity[5] Report Accuracy - The company emphasizes that there are no uncertainties affecting the accuracy of this performance report[6]

证券代码：600161 证券简称：天坛生物 公告编号：2024-052 北京天坛生物制品股份有限公司 第九届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）第九届董事会第十八 次会议于 2024 年 12 月 25 日以电子方式发出会议通知，于 2024 年 12 月 30 日以 通讯表决方式召开。会议应参加表决董事七人，实际参加表决董事七人。会议符 合《公司法》及《公司章程》的有关规定，会议审议通过以下议案： 一、审议通过《关于聘任公司副总经理的议案》 本议案已经董事会提名委员会事前认可。 同意聘任余鼎先生（简历附后）为公司副总经理，任期至第九届高管人员换 届。 本议案已经独立董事会议事前认可。独立董事会议就本关联交易事项发表意 见如下：本次关联交易事项符合公司经营业务的发展需要，有利于公司盘活资产， 提高现有资产的使用效率，增加上市公司经济效益。关联交易定价公允合理，不 存在损害公司和全体股东利益的情形，同意将该事项提交公司董事会审议。 详见同日披 ...

关于租出资产暨关联交易的公告 证券代码：600161 证券简称：天坛生物 公告编号：2024-053 北京天坛生物制品股份有限公司 一、 关联交易概述 （一）本次交易的基本情况 公司拥有北京市朝阳区双桥路乙 2 号院园区土地使用权及其地上附着物所 有权，公司已与关联方国药资产公司签订租赁合同,将北京市朝阳区双桥路乙 2 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容： 北京天坛生物制品股份有限公司（以下简称"公司"）拥有北京市朝阳区双 桥路乙 2 号院园区（以下简称"园区"）土地使用权及其地上附着物所有权，公 司已与关联方北京国药资产管理有限责任公司（以下简称"国药资产公司"）签 订租赁合同,将园区部分资产（实际建筑面积 18,676.80 平方米）租赁给国药资 产公司，上述租赁合同将于 2024 年 12 月 31 日到期。 公司于 2024 年 12 月 30 日召开第九届董事会第十八次会议，审议通过《关 于将双桥路乙 2 号院部分园区资产租赁给国药资产公司的议案》，同意公司与国 药资产公 ...

证券代码：600161 证券简称：天坛生物 公告编号：2024-051 北京天坛生物制品股份有限公司 （一）产品信息 | 产品名称 | 剂型 | 研发投入（万元） | | --- | --- | --- | | 静注 COVID-19 人免疫球蛋白（pH4） | 注射剂 | 12060.7 万元 | （二）同类产品市场情况 本产品国内外无同类血液制品产品上市。 二、药物研发相关情况及终止原因 关于下属企业药品终止临床试验的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）下属国药集团武汉生 物制药有限公司研制的"静注 COVID-19 人免疫球蛋白（pH4）"处于Ⅱ期临床试 验研究阶段。近日，经综合评估，公司决定终止该药物的Ⅱ期临床试验研究及后 续研发。现将有关信息披露如下： 一、终止临床的药物基本信息 三、对上市公司的影响及风险提示 静注 COVID-19 人免疫球蛋白（pH4）研发投入共计 12,060.70 万元，包括研 究开发费和设备购置费。其中研究开发费累计共 11 ...

证券代码：600161 证券简称：天坛生物 公告编号：2024-050 北京天坛生物制品股份有限公司 2024 年 12 月 20 日 1 北京天坛生物制品股份有限公司（以下简称"公司"）董事会收到公司副总 经理刘亚娜女士的书面辞职申请。刘亚娜女士由于工作调整原因，提出辞去公司 副总经理职务，辞去上述职务后刘亚娜女士将继续担任公司党委书记、董事职务。 上述辞职申请自送达公司董事会时生效。 公司董事会对刘亚娜女士在公司担任副总经理职务期间为公司发展所做出 的贡献表示衷心感谢！ 特此公告。 北京天坛生物制品股份有限公司高管辞职公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

证券代码：600161 证券简称：天坛生物 公告编号：2024-049 北京天坛生物制品股份有限公司 第九届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司(以下简称"公司")第九届董事会第十七次 会议于 2024 年 12 月 13 日以电子方式发出会议通知，于 2024 年 12 月 18 日以通 讯表决方式召开。会议应参加表决董事七人，实际参加表决董事七人。会议符合 《公司法》及《公司章程》的有关规定，会议审议通过以下议案： 审议通过《关于上海血制向长春市红十字会实施捐赠的议案》，同意公司所 属国药集团上海血液制品有限公司向长春市红十字会捐赠 30 万元。 表决结果：7 票同意，0 票反对，0 票弃权。 特此公告。 北京天坛生物制品股份有限公司 2024 年 12 月 18 日 1 ...